T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Thymagen peptide has garnered attention within scientific circles due to its hypothesized impact on various biological ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

Id3 is induced in response to transforming growth factor β (TGF-β), a pleiotropic cytokine that inhibits the growth and survival of normal and transformed lymphocyte progenitors.

Whether antiretroviral therapy (ART) is always completely suppressive, or HIV might continue to replicate at low levels despite ART in some people with HIV (PWH), is still debated. Here, we ...